Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine

被引：0
|
作者：
Nakai, Yousuke
Isayama, Hiroyuki
Tsujino, Takeshi
Yoshida, Haruhiko
Kawabe, Takao
Yagioka, Hiroshi
Kogure, Hirofumi
Sasaki, Takashi
Ito, Yukiko
Togawa, Osamu
Matsubara, Saburou
Arizumi, Toshihiko
Sasahira, Naoki
Hirano, Kenji
Matsubara, Minoru
Omata, Masao
机构：
来源：
GASTROINTESTINAL ENDOSCOPY | 2007年 / 65卷 / 05期
关键词：
D O I：
10.1016/j.gie.2007.03.487
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：AB226 / AB226
页数：1
相关论文
共 50 条
  • [41] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Melisi, Davide
    Garcia-Carbonero, Rocio
    Macarulla, Teresa
    Pezet, Denis
    Deplanque, Gael
    Fuchs, Martin
    Trojan, Jorg
    Oettle, Helmut
    Kozloff, Mark
    Cleverly, Ann
    Smith, Claire
    Estrem, Shawn T.
    Gueorguieva, Ivelina
    Lahn, Michael M. F.
    Blunt, Al
    Benhadji, Karim A.
    Tabernero, Josep
    BRITISH JOURNAL OF CANCER, 2018, 119 (10) : 1208 - 1214
  • [42] A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Nakachi, K.
    Okusaka, T. O.
    Funakoshi, A. F.
    Ioka, T. I.
    Yamao, K. Y.
    Ohkawa, S. O.
    Boku, N. B.
    Komatsu, Y. K.
    Nakamori, S. N.
    Furuse, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
  • [43] Low dose gemcitabine improves the prognosis of elderly patients with unresectable advanced pancreatic cancer
    Matsumoto, Kazuyuki
    Toyokawa, Tatsuya
    Miyake, Yasuhiro
    Yasumara, Hisae
    Takahara, Masahiro
    Kaji, Eisuke
    Nakatsu, Morihito
    Ando, Masaharu
    Hirohata, Mamoru
    GASTROENTEROLOGY, 2008, 134 (04) : A453 - A454
  • [44] Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer
    Panagiotis Samaras
    Marina Tusup
    Thi Dan Linh Nguyen-Kim
    Burkhardt Seifert
    Helga Bachmann
    Roger von Moos
    Alexander Knuth
    Steve Pascolo
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1005 - 1012
  • [45] Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
    Thapaliya, P.
    Kundranda, M. N.
    Curtis, K. K.
    Callister, M. D.
    Ashman, J. B.
    Collins, J.
    Moss, A.
    Mekeel, K. L.
    Silva, A. C.
    Borad, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431
  • [47] EFFICACY AND SAFETY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR METASTATIC PANCREATIC CANCER
    You, Min Su
    Ryu, Ji Kon
    Kang, Jinwoo
    Choi, Jin Ho
    Choi, Young Hoon
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2018, 154 (06) : S285 - S285
  • [48] Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer
    Das, R.
    Sahai, V.
    Bednar, F.
    Cuneo, K. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E70 - E70
  • [49] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer
    Das, Rishi
    Abbott, Madeline R.
    Hadley, Scott W.
    Sahai, Vaibhav
    Bednar, Filip
    Evans, Joseph R.
    Schipper, Matthew J.
    Lawrence, Theodore S.
    Cuneo, Kyle C.
    ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (06)
12345